银屑病生物制剂剂量调整的真实世界回顾性研究
该回顾性多中心观察研究纳入350例斑块状银屑病患者(46.9%合并银屑病关节炎),分析3年内生物制剂剂量调整策略。结果显示20%(70/350)患者需调整剂量,其中71.4%为减量、28.6%为增量;减量主因是病情长期缓解(54%),增量主因为银屑病参数无效(60%)或关节参数无效(40%)。
要点
- 真实临床中20%银屑病生物制剂治疗患者需调整剂量。
- 剂量调整以减量为主(71.4%),多因病情长期缓解。
- 增量主要因银屑病或关节症状控制不佳。
核心结论
- 剂量调整是银屑病生物制剂治疗的常见临床实践,包括病情缓解时的减量和疗效不足时的增量。
研究设计与样本
- 回顾性、观察性、多中心研究,纳入350例斑块状银屑病患者,其中164例(46.9%)合并银屑病关节炎,分析3年内剂量调整策略。
主要发现
- 70/350例(20%)患者需要剂量调整,其中增量20/70例(28.6%),减量50/70例(71.4%)。
- 增量原因:银屑病参数无效占60%,银屑病关节炎参数无效占40%。
- 减量或临时超说明书中断原因:长期缓解占54%,其他原因占18%,患者选择或要求占14%,伴随事件占12%。
- 基线平均PASI评分为14.9(SD 7.2)。
临床怎么用
- 临床中应根据病情缓解情况考虑减量,根据银屑病及关节疗效不足考虑增量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Despite the large routine use of biologic drugs in psoriasis treatment, the majority of studies do not take into consideration dose-adjustment practice in 'real-life' dermatological setting. In routine clinical practice, the disease management may include a large number of conditions requiring non-standard dosage regimens, including dose escalation, dose reduction and/or off-label treatment interruption. OBJECTIVE: The ONDA (Outcome of non-standard dosing regimen in Psoriasis and Psoriatic Arthritis) study aim was to retrospectively analyse dose-adjustment strategies among biologic therapies for psoriasis in dermatological practice during a 3-year period. RESULTS: This retrospective, observational, multicentre study was carried out in 350 patients (68% male, 32% female) affected by plaque-type psoriasis (Pso) with a coexistence of psoriatic arthritis in 164 patients (46.9%). At baseline mean PASI score was 14.9 (SD 7.2). Dose adjustment was demonstrated to be a common practice with 70/350 patients (20%) who needed a dose variation during the treatment time, in particular a dose increase in 20/70 patients (28.6%) and a dose reduction in 50/70 patients (71.4%). Dose increase was due to inefficacy on Pso parameters in 60% of cases and to inefficacy of PsA parameters in 40% of cases, while dose reduction (or temporary off-label treatment interruption) was due to prolonged remission in 54% of cases, other reason in 18% of cases, patient choice or request in 14% of cases, occurrence of concomitant event in 12% of cases. CONCLUSION: Dose adjustment is a common clinical practice, consisting of frequent dose reduction when a disease prolonged remission is obtained or dose increase to improve efficacy on Pso and PsA disease parameters.
引用
- Esposito M, Gisondi P, Conti A, et al. Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. J Eur Acad Dermatol Venereol. 2017. PMID: 28146329. doi:10.1111/jdv.14145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。